Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of EGFR exon 20 insertion-mutated non-small-cell lung cancer

Humanistic burden and health-related quality of life

1 evidence topic · 3 sources

Systematic literature review: scope of the burden evidence

“Seventy-eight unique studies were included; 53 reporting mutation frequency, 13 prognostic impact, 36 clinical outcomes, and one humanistic burden.” (opens the source at this quote in a new tab)